CDK1 and melanoma: Furthermore, inhibition of BRAF with vemurafenib, or MEK with UO126, potentiated effects of Nutlin3 and cyclin B /CDK1 inhibition, inducing apoptosis of melanoma in vitro and in vivo [131].